| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 10/07/2004 | US20040198776 Methods for increasing leptin levels using nicotinic acid compounds |
| 10/07/2004 | US20040198766 Chemical compounds |
| 10/07/2004 | US20040198761 reducing pain; side effect reduction; plant extracts |
| 10/07/2004 | US20040198760 Anticancer agents ; skins, prostate glands, lungs, breasts, leukemia, central nervous system, colon |
| 10/07/2004 | US20040198757 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| 10/07/2004 | US20040198752 Administering retinoids with epidermal growth factor receptor inhibitors |
| 10/07/2004 | US20040198751 Pyrazolo-pyrimidine compound; anticancer agents |
| 10/07/2004 | US20040198750 Compositions useful as inhibitors of protein kinases |
| 10/07/2004 | US20040198737 Azaindoles |
| 10/07/2004 | US20040198735 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents |
| 10/07/2004 | US20040198730 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 10/07/2004 | US20040198727 Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments |
| 10/07/2004 | US20040198720 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 10/07/2004 | US20040198718 Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them |
| 10/07/2004 | US20040198716 Cysteine protease inhimbitors |
| 10/07/2004 | US20040198705 Modulation of steroid hormone uptake |
| 10/07/2004 | US20040198688 for treatment of atopic conditions (dermatitis, allergies); point mutations |
| 10/07/2004 | US20040198682 RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA) |
| 10/07/2004 | US20040198679 Use of inhibitors of expression or activity of p8/com1 for treating tumors |
| 10/07/2004 | US20040198674 Compositions for preventing hormone induced adverse effects |
| 10/07/2004 | US20040198673 Composition for epigallocatechin gallate |
| 10/07/2004 | US20040198659 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 10/07/2004 | US20040198653 administering somatostatin type-1,2 or 5 receptor oligopeptide agonists alone or in synergistic combination; antiproliferative agents |
| 10/07/2004 | US20040198651 Secreted proteins |
| 10/07/2004 | US20040198636 Administering 2,2*-dipyridyl, deferiprone, deferoxamine, mimosine, and/or ciclopirox or derivatives thereof to inhibit both deoxyhypusine hydroxylase and prolyl 4-hydroxylase; antiproliferative and antitumor agents |
| 10/07/2004 | US20040197901 Ancillary composition for the preparation of committed mature dentritic cells |
| 10/07/2004 | US20040197863 for use as anticancer/tumor agents using real-time polymerase chain reaction genetic engineering |
| 10/07/2004 | US20040197860 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 10/07/2004 | US20040197853 largely reduced of antigenicity compared to native trichosanthin (TCS), while retaining anti-tumor, anti-virus, abortifacient, and ribosome-inactivating protein activities; for treating leukemia |
| 10/07/2004 | US20040197847 High throughput screening assays using fatty acid synthetic enzymes |
| 10/07/2004 | US20040197783 Comprises nucleotide sequences coding modulator for treatment and prevention of tumor disorders; antisense/antitumor agents; immunotherapy |
| 10/07/2004 | US20040197782 Nucleic acid sequences mixture for detection of cutaneous t-cell lymphomas (CTCL); antitumor agents |
| 10/07/2004 | US20040197429 Selective COX-2 inhibition from plant extracts |
| 10/07/2004 | US20040197427 Herbal composition for improving anticancer activity, immune response and hematopoiesis of the body, and protecting the body from oxidative damage, and the method of preparing the same |
| 10/07/2004 | US20040197426 Use of phyllanthus constituents for treating or preventing infections caused by hepatit |
| 10/07/2004 | US20040197421 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 10/07/2004 | US20040197420 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 10/07/2004 | US20040197404 Extended release oral dosage form |
| 10/07/2004 | US20040197349 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 10/07/2004 | US20040197345 Prostate derived Ets factor |
| 10/07/2004 | US20040197337 Methods to impair hematologic cancer progenitor cells and compounds related thereto |
| 10/07/2004 | US20040197335 Non-myeloablative tolerogenic treatment with tyrphostins |
| 10/07/2004 | US20040197332 antiproliferative agents; antitumor and anticancer agents; monoclonal antibodies produced by hybridomas cell ling |
| 10/07/2004 | US20040197331 Induction of cytotoxic T-lymphocyte responses |
| 10/07/2004 | US20040197328 Screening; separation using cancer cytotoxicity; diagnosis; anticancer, antitumor agents; administering monoclonal antibodies |
| 10/07/2004 | US20040197314 gene expression of polypeptide in membrane vesicle ; forming antibodies; controlling immunology response |
| 10/07/2004 | US20040197308 Dna which controls gene expression; insertion of gene into tumor cells |
| 10/07/2004 | US20040197307 Mixture of human interferons |
| 10/07/2004 | US20040197303 For therapy of inflammation and diseases or conditions associated with autoimmune responses |
| 10/07/2004 | US20040197289 Kind of oligosaccharides, their sulfates and dendrimers, and the uses of these compounds |
| 10/07/2004 | DE4035253B4 Injektionslösungen und Verfahren zu deren Herstellung Injection solutions and processes for their preparation |
| 10/07/2004 | DE10314377A1 Pharmaceutical composition useful for tumor therapy comprises water, oxaliplatin and an acid other than oxalic acid |
| 10/07/2004 | DE10313035A1 Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen Method for enhancing the apoptotic effect of cytotoxic drugs without increasing toxic side effects |
| 10/07/2004 | CA2731275A1 Tumour-associated peptides binding to mhc-molecules |
| 10/07/2004 | CA2520147A1 Compound having affinity with calcified tissue |
| 10/07/2004 | CA2519826A1 Cell death-inducing fusion gene specifically acting on cancer and product thereof |
| 10/07/2004 | CA2519795A1 Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53 |
| 10/07/2004 | CA2519053A1 Novel oxazole derivatives, their manufacture and use as pharmaceutical agents |
| 10/07/2004 | CA2518909A1 Heterocyclic compounds and methods of use |
| 10/07/2004 | CA2515605A1 Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| 10/06/2004 | EP1464673A2 Polyanhydrides with biologically active degradation products |
| 10/06/2004 | EP1464646A1 Thieno(2,3-C) Isoquinolines for use as inhibitors of Parp |
| 10/06/2004 | EP1464645A1 Indole derivative |
| 10/06/2004 | EP1464640A2 20-Epi-16-ene-25-OH-D3-analogs |
| 10/06/2004 | EP1464636A1 Novel substance having antitumor/anti-inflammatory activity |
| 10/06/2004 | EP1463928A2 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| 10/06/2004 | EP1463827A2 LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 10/06/2004 | EP1463820A1 Method of screening compounds |
| 10/06/2004 | EP1463803A2 Hematopoietic cells from human embryonic stem cells |
| 10/06/2004 | EP1463760A2 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| 10/06/2004 | EP1463759A1 Ligand for g-protein coupled receptor gpr43 and uses thereof |
| 10/06/2004 | EP1463758A2 Mammal prolactin variants |
| 10/06/2004 | EP1463757A2 Antisense compounds directed against human csf-1 |
| 10/06/2004 | EP1463756A2 Secreted proteins |
| 10/06/2004 | EP1463754A2 Cystine-knot fold protein |
| 10/06/2004 | EP1463751A2 Albumin fusion proteins |
| 10/06/2004 | EP1463747A2 Novel antibodies that bind to antigenic polypeptides,nucleic acids encodings the antigens, and methodes of use |
| 10/06/2004 | EP1463742A2 Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
| 10/06/2004 | EP1463733A2 Mitotic kinesin inhibitors |
| 10/06/2004 | EP1463731A1 Dibenzodiazepine derivates, their preparation and use |
| 10/06/2004 | EP1463730A1 Pyrazoloparidazine derivatives |
| 10/06/2004 | EP1463728A2 Fused cyclic modulators of nuclear hormone receptor function |
| 10/06/2004 | EP1463719A2 Eponemycin and epoxomicin analogs and uses thereof |
| 10/06/2004 | EP1463707A2 A group of novel anti-cancer compounds with specific structure |
| 10/06/2004 | EP1463558A2 Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| 10/06/2004 | EP1463541A2 Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumours |
| 10/06/2004 | EP1463529A2 Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy |
| 10/06/2004 | EP1463525A2 Compositions and methods for the diagnosis and treatment of tumor |
| 10/06/2004 | EP1463524A2 METHODS OF THERAPY FOR NON−HODGKIN S LYMPHOMA |
| 10/06/2004 | EP1463511A1 Combination cancer therapy |
| 10/06/2004 | EP1463509A1 Type 4 phosphodiesterase inhibitors and uses thereof |
| 10/06/2004 | EP1463507A1 Thienopyrimidine compounds as protein tyrosine kinase inhibitors |
| 10/06/2004 | EP1463506A1 Substituted quinazoline derivatives as inhibitors of aurora kinases |
| 10/06/2004 | EP1463505A2 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer |
| 10/06/2004 | EP1463504A1 Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome |
| 10/06/2004 | EP1463501A1 Cis-imidazolines as mdm2 inhibitors |
| 10/06/2004 | EP1463498A1 Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases |
| 10/06/2004 | EP1463497A2 Treating muscle wasting with selective androgen receptor modulators |
| 10/06/2004 | EP1463495A2 Agents and methods for treatment of cancer |
| 10/06/2004 | EP1463487A1 Liposomal delivery of vitamin e based compounds |